P. van Remoortere

发表

Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model

D. Nauwelaers, P. V. Remoortere, D. Roymans, 2010, European Respiratory Journal.

Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment.

Lieven Baert, Jan Rosier, L. Baert, 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

5-imidazolyl-quinolinones, -quinazolinones and -benzo-azepinones as farnesyltransferase inhibitors.

G. Mannens, P. Muller, P. van Remoortere, 2003, Bioorganic & medicinal chemistry letters.

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.

F. Broeckaert, P. Meyvisch, C. Weegink, 2010, Gastroenterology.

Dog model with implanted pump to test boosters for antiretroviral medication.

L. Baert, T. Jonckers, G. Van den Mooter, 2008, International journal of pharmaceutics.

Substituted azoloquinolines and -quinazolines as new potent farnesyl protein transferase inhibitors.

M. Janicot, C. Meyer, G. Mannens, 2003, Bioorganic & medicinal chemistry letters.

Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection

W. Talloen, P. Tangkijvanich, E. Gane, 2022, Journal of Antimicrobial Chemotherapy.

Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers

W. Talloen, E. Gane, J. Snoeys, 2021, Antiviral therapy.

Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase.

M. Cummings, B. Devogelaere, Lili Hu, 2014, Journal of medicinal chemistry.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults.

L. Slaets, E. Gane, P. van Remoortere, 2021, Antiviral therapy.

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection

H. Van Vlierberghe, F. Nevens, J. Schattenberg, 2017, BMC Gastroenterology.

Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus‐infected patients with decompensated liver disease

P. V. Remoortere, S. Ouwerkerk-Mahadevan, V. van Eygen, 2017, Journal of viral hepatitis.

Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).

K. Andries, C. Meyer, P. Timmerman, 2008, Journal of medicinal chemistry.

Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7.

J. Peeters, M. Brewster, P. van Remoortere, 2002, Journal of pharmaceutical sciences.

Pharmacokinetics-Pharmacodynamics of a Respiratory Syncytial Virus Fusion Inhibitor in the Cotton Rat Model

D. Nauwelaers, D. Roymans, K. Andries, 2010, Antimicrobial Agents and Chemotherapy.

Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection

M. Gamil, S. Ouwerkerk-Mahadevan, W. Smith, 2018, Journal of viral hepatitis.

Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845

P. van Remoortere, R. Verloes, L. Vijgen, 2017, Virology Journal.

Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants

N. Goeyvaerts, J. Niu, L. Slaets, 2023, Antiviral therapy.

Co-administration of darunavir and a new pharmacokinetic booster: formulation strategies and evaluation in dogs.

Lieven Baert, Jody Voorspoels, Jan Rosier, 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults

L. Slaets, E. Gane, I. Verbrugge, 2023, Antiviral therapy.

Therapeutic vaccine JNJ-0535 induces a strong HBV-specific T-cell response in healthy adults and a modest response in chronic HBV-infected patients

L. Slaets, E. van Gulck, C. Van den Broeke, 2022, Journal of Hepatology.

Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge Study

H. Fennema, J. Symons, P. van Remoortere, 2018, The Journal of infectious diseases.

Powder for reconstitution of the anti-HIV-1 drug TMC278 - Formulation development, stability and animal studies.

J. Hoogmartens, L. Baert, E. Adams, 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen

H. Van Vlierberghe, F. Nevens, S. Ouwerkerk-Mahadevan, 2017, Antimicrobial Agents and Chemotherapy.

Limitations of the graphical analysis of elution curves.

P. van Remoortere, F. Hagemeijer, 1969, Journal of theoretical biology.

Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase.

M. Cummings, B. Devogelaere, Lili Hu, 2014, Journal of medicinal chemistry.